BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)
Thomas Gaisl, Chris D. Turnbull, Gerrit Weimann, Sigrun Unger, Rudolf Finger, Charles Xing, Peter A. Cistulli, Sophie West, Alan K.I. Chiang, Danny J. Eckert, John R. Stradling, Malcolm Kohler
Source: Eur Respir J, 58 (5) 2101937; 10.1183/13993003.01937-2021
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Thomas Gaisl, Chris D. Turnbull, Gerrit Weimann, Sigrun Unger, Rudolf Finger, Charles Xing, Peter A. Cistulli, Sophie West, Alan K.I. Chiang, Danny J. Eckert, John R. Stradling, Malcolm Kohler. BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN). Eur Respir J, 58 (5) 2101937; 10.1183/13993003.01937-2021
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety and efficacy of sulthiame in moderate to severe obstructive sleep apnea: a randomized placebo-controlled parallel-group trial Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing Year: 2021
The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study Source: Eur Respir J 2001; 18: Suppl. 33, 419s Year: 2001
A randomised, double-blind, crossover, placebo-controlled trial of a mandibular advancement device for the treatment of snoring and mild obstructive sleep apnoea-hypopnoea syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 102s Year: 2002
Effects of suboptimal adherence of CPAP therapy on symptoms of obstructive sleep apnoea: a randomised, double-blind, controlled trial Source: Eur Respir J, 55 (3) 1901526; 10.1183/13993003.01526-2019 Year: 2020
A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial Source: Eur Respir J, 54 (2) 1900518; 10.1183/13993003.00518-2019 Year: 2019
Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study Source: Eur Respir J 2014; 44: 140-149 Year: 2014
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Effectiveness of non-invasive ventilation in stable chronic obstructive pulmonary disease with nocturnal desaturation: Prospective open-label randomized parallel-group study Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
A randomized, double-blind, placebo-controlled trial on the effect of intranasal corticosteroid as a treatment for moderate to severe obstructive sleep apnea with coexisting chronic rhinitis Source: International Congress 2019 – Current perspectives in sleep-disordered breathing Year: 2019
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005
Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
Acetazolamide administration following upper airway surgery for SDB. Preliminary results of a randomized, double-blind, placebo-controlled study Source: Eur Respir J 2005; 26: Suppl. 49, 201s Year: 2005
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial Source: Eur Respir J 2013; 42: 1244-1254 Year: 2013
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022